Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes

JAMA Psychiatry

Volumn 72, Issue 3, 2015, Pages 268-275

  Setiawan, Elaine ^a   Wilson, Alan A ^a,b   Mizrahi, Romina ^a,b,c   Rusjan, Pablo M ^a   Miler, Laura ^a   Rajkowska, Grazyna ^d   Suridjan, Ivonne ^a,c   Kennedy, James L ^a,b,c   Rekkas, P Vivien ^a   Houle, Sylvain ^a,b   Meyer, Jeffrey H ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; FLUORINE 18; N [2 (2 FLUOROETHOXY)BENZYL] N (4 PHENOXYPYRIDIN 3YL)ACETAMIDE; PROTEIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ANILIDE; BIOLOGICAL MARKER; N-(2-((N-(4-PHENOXYPYRIDIN-3-YL)ACETAMIDO)METHYL)PHENOXY)ETHYL FLUORIDE; PYRIDINE DERIVATIVE; TSPO PROTEIN, HUMAN;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN; BRAIN REGION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENCEPHALITIS; FEMALE; HUMAN; INSULA; MAJOR DEPRESSION; MALE; MENTAL HOSPITAL; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; TERTIARY HEALTH CARE; VOLUME OF DISTRIBUTION; BRAIN CORTEX; CINGULATE GYRUS; DIAGNOSTIC USE; INFLAMMATION; METABOLISM; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; ANILIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; FEMALE; GYRUS CINGULI; HUMANS; INFLAMMATION; MALE; MICROGLIA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PYRIDINES; RECEPTORS, GABA; SEVERITY OF ILLNESS INDEX;

EID: 84925357658     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2427     Document Type: Article

References (45)

1. Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386-392.
2. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433-449.
3. MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16(3):252-264.
4. Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther. 2012;91(2):201-214.
5. Rajkowska G,Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6(3):219-233.
6. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445-452.
7. Fu X, Zunich SM, O'Connor JC, Kavelaars A, Dantzer R, Kelley KW. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation. 2010;7:43. doi: 10.1186/1742-2094-7-43.
8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31.
9. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32(1):7-24.
10. th Annual Meeting of the Society for Neuroscience; November 12-16, 2005;Washington, DC.
11. Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord. 2010;120(1-3):245-248.
12. Steiner J,Walter M, Gos T, et al. Severe depression is associatedwith increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94. doi:10.1186/1742-2094-8-94.
13. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011;16(7):751-762.
14. Sequeira A, Gwadry FG, Ffrench-Mullen JM, et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry. 2006;63(1):35-48.
15. Sibille E, Arango V, Galfalvy HC, et al. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology. 2004;29(2):351-361.
16. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151-157.
17. Pandey GN, Rizavi HS, Ren X, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57-63.
18. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9(12):971-988.
19. 18F]FEPPA as CNS peripheral benzodiazepine receptor PET ligands in the pig. J Nucl Med. 2008;49(suppl 1):81P. http: //jnm.snmjournals.org/content/49/supplement-1/81P.3. Accessed August 15, 2014.
20. 11C-PK11195. Neuroimage. 2008;41(suppl 2):T94-T94. doi: 10.1016/j.neuroimage.2008.04.063.
21. 18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008;35(3):305-314.
22. 11C]PBR28 PET study. Brain Behav Immun. 2013;33:131-138.
23. Montgomery SA, ÅsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
24. 18F]-FEPPA. J Cereb Blood Flow Metab. 2012;32(6):968-972.
25. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1-5.
26. Ressler KJ,Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116-1124.
27. Hannestad J, SubramanyamK, Dellagioia N, et al. Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. J Nucl Med. 2012;53(4):601-607.
28. Avery JA, DrevetsWC, Moseman SE, Bodurka J, Barcalow JC, Simmons WK. Major depressive disorder is associated with abnormal interoceptive activity and functional connectivity in the insula. Biol Psychiatry. 2014;76(3):258-266.
29. Simmons WK, Rapuano KM, Kallman SJ, et al. Category-specific integration of homeostatic signals in caudal but not rostral human insula. Nat Neurosci. 2013;16(11):1551-1552.
30. FirstM, Spitzer R, Williams J, Gibbon M. Structured Clinical Interview for DSM-IV-Non-Patient Edition (SCID-NP), Version 1.0. Washington, DC: American Psychiatric Press; 1995.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
32. Vrieze E, Demyttenaere K, Bruffaerts R, et al. Dimensions in major depressive disorder and their relevance for treatment outcome. J Affect Disord. 2014;155:35-41.
33. 18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab. 2011;31(8):1807-1816. doi: 10.1038/jcbfm.2011.55.
34. Chiuccariello L, Houle S,Miler L, et al. Elevated monoamine oxidase A binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. Neuropsychopharmacology. 2014;39(4):973-980.
35. Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci. 2013;7:44. doi:10.3389/fncel.2013.00044.
36. Martín A, Boisgard R, KassiouM, Dollé F, Tavitian B. Reduced PBR/TSPOexpression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714. Mol Imaging Biol. 2011;13(1):10-15.
37. He Y, Appel S, LeW. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001;909(1-2):187-193.
38. Henry CJ, Huang Y, Wynne A, et al.Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15. doi:10.1186/1742-2094-5-15.
39. Harrison NA, Brydon L,Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66(5):407-414.
40. Bromander S, Anckarsäter R, Kristiansson M, et al. Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J Neuroinflammation. 2012;9:242. doi:10.1186/1742-2094-9-242.
41. Bay-Richter C, Janelidze S, Hallberg L, Brundin L. Changes in behaviour and cytokine expression upon a peripheral immune challenge. Behav Brain Res. 2011;222(1):193-199.
42. Qin L,Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55(5):453-462.
43. De Simoni MG, Terreni L, Chiesa R, Mangiarotti F, Forloni GL. Interferon-gamma potentiates interleukin (IL)-6 and tumor necrosis factor-α but not IL-1β induced by endotoxin in the brain. Endocrinology. 1997;138(12):5220-5226.
44. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
45. Lavisse S, GuillermierM, Hérard AS, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32(32):10809-10818.